In a report published on Monday, Piper Jaffray analyst Edward A. Tenthoff reiterated an Overweight rating and a $3 price target on Novavax NVAX.
In the report, Piper Jaffray stated, "This morning, Novavax began enrollment of a Phase I study of its monovalent virus- like particle (VLP) vaccine candidate for H7N9 avian flu. Remarkably, Novavax moved into Phase I studies in only 3 months since the H7N9 gene sequence was identified, demonstrating the speed with which Novavax can discover its VLP vaccine candidates. Similarly, Novavax rapidly developed a vaccine candidate against the MERS-CoV Coronavirus, both of which could be procured in case of a pandemic emergency. This alacrity is one of the reasons Novavax was awarded a $97 million BARDA contract to develop pandemic and seasonal flu vaccines."
Novavax closed on Friday at $2.62.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in